GNFT
Closed
Genfit
3.79
+0.07 (+1.88%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.725
Day's Range: 3.79 - 3.85
Send
sign up or login to leave a comment!
When Written:
4
Genfit is a biopharmaceutical company that focuses on the development of innovative drugs and diagnostic solutions for the treatment of liver diseases, such as non-alcoholic steatohepatitis (NASH). The company was founded in 1999 and is headquartered in Loos, France.
Genfit's lead drug candidate, elafibranor, is a dual PPAR alpha/delta agonist that has shown promising results in clinical trials for the treatment of NASH. The company is also developing a diagnostic tool, NIS4, which combines four biomarkers to identify patients with NASH and assess the severity of the disease.
In addition to its liver disease programs, Genfit is also exploring the potential of its technology platform in other therapeutic areas, such as cardiovascular and metabolic diseases.
Genfit is publicly traded on the NASDAQ stock exchange under the ticker symbol "GNFT."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Genfit's lead drug candidate, elafibranor, is a dual PPAR alpha/delta agonist that has shown promising results in clinical trials for the treatment of NASH. The company is also developing a diagnostic tool, NIS4, which combines four biomarkers to identify patients with NASH and assess the severity of the disease.
In addition to its liver disease programs, Genfit is also exploring the potential of its technology platform in other therapeutic areas, such as cardiovascular and metabolic diseases.
Genfit is publicly traded on the NASDAQ stock exchange under the ticker symbol "GNFT."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








